CHEK2 and cancer: However, depletion of CHEK2 has been reported to increase sensitivity to PARP inhibitors in preclinical models and PARP inhibitors are in clinical trials in cancers with DNA repair deficiencies, including CHEK2 alterations [63] (NCT03786796, 2019; NCT03012321, 2019; NCT02576444, 2019; NCT02401347).